News
| Feb 09 | Benzinga's M&A Chatter for Thursday February 9, 2012 Benzinga |
| Feb 09 | Speedy Review for Roche Drug |
| Feb 09 | Speedy Review for Roche Drug - Analyst Blog Zacks |
| Feb 09 | [$$] Pharma Looks Ready to Turn Defense Into Offense |
| Feb 09 | How the Wheels Came off GlaxoSmithKline's Bus Fool |
| Feb 09 | 5 Defensive Stocks For A Highly Volatile Market |
| Feb 09 | Facebook Alternatives: Less Hype, More Hope |
| Feb 08 | GlaxoSmithKline: A Good Mix Of Income And Opportunity |
| Feb 08 | U.K. Mega Caps Earnings And Dividend Update |
| Feb 08 | Anticipation |
| Feb 08 | Interesting to see $GSK boasting about how it is repatriates its cash from European operations so fast these days. Probably a wise move. by bradloncar |
| Feb 07 | $GSK IR on Twitter. Smart example. "GSK to announce 2011 year-end results [today] at noon GMT. We'll be using the hashtag #GSKFY11" by BHSMITH |
| Feb 06 | $ANAC reports partner GlaxoSmithKline $GSK has voluntarily paused enrollment of ongoing GSK '052 Phase 1, 2 Clinical Trials; ANAC halted by Street_Insider |
| Feb 03 | $TEVA buying opportunity here $PFE $LLY $GSK $NVS $GILD by MJT |
| Feb 02 | The Best Healthcare Dividend Stocks With Fastest Earnings Growth + http://stks.co/2CgH + $GSK $VIVO $NVS $KNSY $NDZ $PETS $ABT $JNJ $LNCR by DividendYield |
Profile
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers - Major
GlaxoSmithKline plc, often abbreviated to GSK, is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. It is the world's third largest pharmaceutical company measured by revenues (after Johnson & Johnson and Pfizer). It has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions.As one of the world's top prescription drug makers, GlaxoSmithKline enjoys annual revenues that exceed 13.2 billion. GSK was formed in 2000 by the merger of GlaxoWellcome plc (formed from the acquisition of Wellcome plc by Glaxo plc), and SmithKline Beecham plc (from the merger of Beecham plc, and SmithKlineBeckman Corporation). GlaxoSmithKline plc was founded in 1999 and is headquartered in Brentford, United Kingdom.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). GlaxoSmithKline is up N/A over the last year vs S&P 500 Total Return up N/A, Merck up N/A, and Pfizer up N/A.
- GSK Total Returns
- ^SPXTR Total Returns
- MRK Total Returns
- PFE Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these GSK related companies
Pro Strategies Featuring GSK
Did GlaxoSmithKline make it into our Pro Portfolio Strategies?
GSK Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other GSK Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Quote.com
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GSK | 44.75 | -0.31 | -0.69% | 114.07B |
| GLW | 13.60 | -0.19 | -1.38% | 21.37B |
| LCC | 8.85 | -0.11 | -1.23% | 1.43B |
| CPE | 6.69 | -0.09 | -1.33% | 263.45M |
| NDN | 22.01 | 0.02 | 0.09% | 1.55B |
| MTD | 181.14 | -3.74 | -2.02% | 5.72B |
| BKH | 34.99 | -0.31 | -0.88% | 1.38B |
| HUM | 85.74 | 0.58 | 0.68% | 14.02B |
| DAC | 4.21 | -0.14 | -3.33% | 458.35M |
| RNN | 0.60 | -0.00 | -0.33% | 56.95M |
